Oxford Biomedica (NASDAQ:OXBDF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, October 18th. The firm presently has a $0.25 price objective on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 92.31% from the company’s current price.
According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “
Oxford Biomedica (NASDAQ OXBDF) traded up $0.02 during trading on Wednesday, reaching $0.13. 214 shares of the company were exchanged.
About Oxford Biomedica
Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with our FREE daily email newsletter.